Our findings provide convincing evidence for how cantharidin, as well as other PP2A inhibitors, carry out anti-tumour effects and reveal the possibility of using PP2A as a therapeutic target for pancreatic cancer treatment. This evidence concerns the gene PTPA and pancreatic neoplasm.